Decoy Therapeutics (NASDAQ:DCOY) Short Interest Down 78.5% in June

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a significant drop in short interest in the month of June. As of June 15th, there was short interest totaling 1,966 shares, a drop of 78.5% from the May 31st total of 9,158 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average trading volume of 18,536 shares, the short-interest ratio is presently 0.1 days.

Decoy Therapeutics Stock Performance

NASDAQ:DCOY traded up $4.66 during trading hours on Monday, reaching $10.18. 12,287,428 shares of the company were exchanged, compared to its average volume of 202,415. The firm has a market cap of $5.40 million, a price-to-earnings ratio of -0.10 and a beta of 0.56. Decoy Therapeutics has a twelve month low of $4.32 and a twelve month high of $415.80. The stock has a 50-day moving average of $6.12.

Decoy Therapeutics (NASDAQ:DCOY) last announced its earnings results on Friday, May 8th. The company reported ($4.18) earnings per share (EPS) for the quarter. As a group, research analysts anticipate that Decoy Therapeutics will post -12.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, June 12th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Decoy Therapeutics has an average rating of “Hold” and an average price target of $30.00.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.